CoChat
Sign Up
Cited by 62

The DOI matches its Crossref record; 2 of the 2 references it cites were found in a registry or an index.

Idiosyncratic DILI: Analysis of 46,266 Cases Assessed for Causality by RUCAM and Published From 2014 to Early 2019

Teschke, Rolf·2019·Frontiers in Pharmacology
DOI 10.3389/fphar.2019.00730PMC PMC6664244
Open this paper in CoChat — free account

Overview

The claims and statistics of this paper haven’t been checked yet.

Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.

A few free checks a day · papers already verified open instantly · results are public

Integrity signals

Registry

Crossref · 10.3389/fphar.2019.00730

Cites

2 of 2 references verified0 citation errors · 0 not checkable

Statistics

Verification

Claims the paper makes

The claims and statistics of this paper haven’t been checked yet.

Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.

A few free checks a day · papers already verified open instantly · results are public

Claims other papers make about this one

Each is checked against this paper’s own text: does it say what the citing paper says it does?

Self-check

Percentages, sums and reported differences re-computed from the paper’s own numbers.

The self-check needs the paper’s full text.

Citations

Cites

Flagged first, then by citations

Research works printed but not linked: 111

  1. Abbara, 2017, Drug-induced liver injury from antituberculous treatment: a retrospective study from a large TB centre in the UK, BMC Infect. Dis., 17, 231, 10.1186/s12879-017-2330-z · DOI · Paper page
  2. Aiso, 2019, Analysis of 307 cases with drug-induced liver injury between 2010 and 2018 in Japan, Hepatol. Res., 49, 105, 10.1111/hepr.13288 · DOI · Paper page
  3. Alempijevic, 2017, Drug-induced liver injury: do we know everything, World J. Hepatol., 9, 491, 10.4254/wjh.v9.i10.491 · DOI
  4. Alhaddad, 2017, Chronic drug-induced liver injury by Amoxicillin-Clavulanate, J. Hepatol., 3, 2, 10.21767/2471-9706.100018 · DOI
  5. Amagon, 2017, Methionine and vitamin B-complex ameliorate antitubercular drugs-induced toxicity in exposed patients, Pharma. Res. Per., 5, 10.1002/prp2.360 · DOI
  6. Andrade, 2017, Prospective European Drug-Induced Liver Injury Registry, PRO-EURO-DILI REGISTRY, 2017. Available at: ProEuroDILI Registry progress report year 1.pdf, referenced by: Teschke R, Danan G. Editorial. Drug-induced liver injury, mortality, and liver transplantation: is it reasonable to use a global introspection causality assessment, AME Med. J., 2, 144, 10.21037/amj.2017.09.05 · DOI
  7. Andrade, 2016, Drug-induced liver injury clinical consortia: a global research response for a worldwide health challenge, Exp. Opin. Drug Metab. Toxicol., 12, 589, 10.1517/17425255.2016.1141896 · DOI
  8. Baig, 2015, Acute liver failure after initiation of Rivaroxaban: a case report and review of the literature, North Am. J. Med. Sci., 21, 407, 10.4103/1947-2714.166221 · DOI
  9. Becker, 2019, Drug and herb-induced liver injury: a critical review of Brasilian cases with proposals for the improvement of causality assessment using RUCAM, 10.1016/j.aohep.2019.03.010 · DOI
  10. Benesic, 2016, Monocyte-derived hepatocyte-like cells for causality assessment of idiosyncratic drug-induced liver injury, Gut, 65, 1555, 10.1136/gutjnl-2015-309528 · DOI
  11. Bénichou, 1990, Criteria of drug-induced liver disorders. Report of an international consensus meeting, J. Hepatol., 11, 272, 10.1016/0168-8278(90)90124-A · DOI · Paper page
  12. Bessone, 2016, The Latin American DILI registry experience: a successful ongoing collaborative strategic initiative, Int. J. Mol. Sci., 17, 313, 10.3390/ijms17030313 · DOI
  13. Bessone, 2019, When the creation of a consortium provides useful answers: experience of The Latin American DILI Network (LATINDILIN), Clin. Liv. Dis., 13, 51, 10.1002/cld.778 · DOI
  14. Björnsson, 2014, Epidemiology and risk factors for idiosyncratic drug-induced liver injury, Semin Liver Dis., 34, 115, 10.1055/s-0034-1375953 · DOI
  15. Björnsson, 2016, Hepatotoxicity by drugs: the most common implicated agents, Int. J. Mol. Sci., 17, 224, 10.3390/ijms17020224 · DOI · Paper page
  16. Björnsson, 2016, Categorization of drugs implicated in causing liver injury: critical assessment based on published case reports, Hepatology, 63, 590, 10.1002/hep.28323 · DOI · Paper page
  17. Bohm, 2014, Case report and cohort analysis of drug-induced liver injury associated with Daptomycin, Antimicrob. Agents Chemother., 58, 4902, 10.1128/AAC.03157-14 · DOI
  18. Cano-Paniagua, 2019, Epidemiology of drug-induced liver injury in a University Hospital from Colombia: updated RUCAM being used for prospective causality assessment, Ann. Hepatol, 18, 501, 10.1016/j.aohep.2018.11.008 · DOI
  19. Chalasani, 2014, Practice Parameters Committee of the American College of Gastroenterology. ACG Clinical Guideline: the diagnosis and management of idiosyncratic drug-induced liver injury, Am. J. Gastroenterol., 109, 950, 10.1038/ajg.2014.131 · DOI · Paper page
  20. Chalasani, 2015, Features and outcomes of 899 patients with drug-induced liver injury: the DILIN prospective study, Gastroenterology, 148, 1340, 10.1053/j.gastro.2015.03.006 · DOI · Paper page
  21. Chang, 2015, Severe hepatic injury associated with different statins in patients with chronic liver disease: a nationwide population-based cohort study, J. Gastroenterol. Hepatol., 30, 155, 10.1111/jgh.12657 · DOI
  22. Chen, 2014, Statins and the risk of liver injury: a population-based case-control study, Pharmacoepidemiol. Drug Saf., 23, 719, 10.1002/pds.3646 · DOI
  23. Cheetham, 2014, An automated causality assessment algorithm to detect drug-induced liver injury in electronic medical record data, Pharmacoepidemiol. Drug Saf., 23, 601, 10.1002/pds.3531 · DOI
  24. Church, 2019, Candidate biomarker for the diagnosis and prognosis of drug-induced liver injury: an international collaborator effort, Hepatology, 69, 760, 10.1002/hep.29802 · DOI · Paper page
  25. Danan, 1993, Causality assessment of adverse reactions to drugs – I. A novel method based on the conclusions of international consensus meetings: application to drug-induced liver injuries, J. Clin. Epidemiol., 46, 1323, 10.1016/0895-4356(93)90101-6 · DOI · Paper page
  26. Danan, 2016, RUCAM in drug and herb induced liver injury: the update, Int. J. Mol. Sci., 17, 10.3390/ijms17010014 · DOI · Paper page
  27. Danan, 2018, Drug-induced liver injury: why is the Roussel Uclaf Causality Assessment Method (RUCAM) still used 25 years after its launch, Drug Saf., 41, 735, 10.1007/s40264-018-0654-2 · DOI · Paper page
  28. Danan, 2019, Roussel Uclaf Causality Assessment Method for drug-induced liver injury: present and future. In: Special issue: Clinical drug induced liver injury: current diagnostic and mechanistic challenges, guest editors: Rolf Teschke, Gaby Danan, James H. Lewis, Front. Pharmacol, 10, 853, 10.3389/fphar2019.00853 · DOI
  29. Dragoi, 2018, Proteomics analysis of monocyte-derived hepatocyte-like cells identifies integrin beta 3 as a specific biomarker for drug-induced liver injury by diclofenac, Front. Pharmacol., 9, 699, 10.3389/fphar.2018.00699 · DOI
  30. Douros, 2014, Drug-induced liver injury: results from the hospital-based Berlin Case-Control Surveillance Study, Br. J. Clin. Pharmacol., 79, 988, 10.1111/bcp.12565 · DOI
  31. Ferrajolo, 2017, Antibiotic-induced liver injury in paediatric outpatients: a case-control study in primary care databases, Drug Saf., 40, 305, 10.1007/s40264-016-0493-y · DOI
  32. Fontana, 2014, Pathogenesis of idiosyncratic drug-induced liver injury and clinical perspectives, Gastroenterology, 146, 914, 10.1053/j.gastro.2013.12.032 · DOI
  33. Forner, 2017, Ramipril-associated cholestasis in the setting of a recurrent drug-induced liver injury, Gastroenterol. Hepatol. Bed. Bench., 1, 143
  34. Giacomelli, 2018, Clinical and genetic factors associated with increased risk of severe liver toxicity in a monocentric cohort of HIV positive patients receiving nevirapine-based antiretroviral therapy, BMC Inf. Dis., 18, 556, 10.1186/s12879-018-3462-5 · DOI
  35. Hayashi, 2015, Reliability of causality assessment for drug, herbal and dietary supplement hepatotoxicity in the Drug-Induced Liver Injury Network (DILIN), Liver Int., 35, 1623, 10.1111/liv.12540 · DOI
  36. Hayashi, 2018, Long-term outcomes after drug-induced liver injury, Curr. Hepatol. Rep., 17, 292, 10.1007/s11901-018-0411-0 · DOI
  37. Hernández, 2014, Profile of idiosyncratic drug induced liver injury in Latin America: an analysis of published reports, Ann. Hepatol., 13, 231, 10.1016/S1665-2681(19)30886-5 · DOI
  38. Hornby, 2014, MicroRNAs as potential circulating biomarkers of drug-induced liver injury: key current and future issues for translation to humans, Exp. Rev. Clin. Pharmacol., 7, 349, 10.1586/17512433.2014.904201 · DOI
  39. Hunt, 2018, Editorial. Expanding our toolkit to better identify drug-induced liver injury in electronic medical records, Liver Int., 38, 585, 10.1111/liv.13710 · DOI
  40. Khoury, 2015, Drug induced liver injury: review with a focus on genetic factors, tissue diagnosis, and treatment options, J. Clin. Transl. Hepatol., 3, 99, 10.14218/JCTH.2015.00007 · DOI
  41. Kim, 2017, Revisiting the metabolism and bioactivation of ketoconazole in human and mouse using liquid chromatography-mass spectrometry-based metabolomics, Int. J. Mol. Sci., 18, 621, 10.3390/ijms18030621 · DOI
  42. Kim, 2016, Update on advances in research on idiosyncratic drug-induced liver injury, Allergy Asthm. Immunol. Res., 8, 3, 10.4168/aair.2015.8.1.3 · DOI
  43. Kim, 2016, Hepatitis C and not hepatitis B virus is a risk factor for anti-tuberculosis drug induced liver injury, BMC Infect. Dis., 16, 50, 10.1186/s12879-016-1344-2 · DOI
  44. Iorga, 2017, Drug-induced liver injury: cascade of events leading to cell death, apoptosis or necrosis. In: Special Issue. Molecular Research on Drug Induced Liver Injury, guest editors R. Teschke, and G. Danan, Int. J. Mol. Sci., 18, 1018, 10.3390/ijms18051018 · DOI
  45. Kullak-Ublick, 2017, Drug-induced liver injury: recent advances in diagnosis and risk assessment, Gut, 66, 1154, 10.1136/gutjnl-2016-313369 · DOI · Paper page
  46. Kwon, 2019, Nimesulide-induced hepatotoxicity: a systemic review and meta-analysis, PLoS One, 14, 10.1371/journal.pone.0209264 · DOI
  47. Lammel-Lindemann, 2018, Noncholestatic acute hepatocellular injury following candesartan administration, Br. J. Clin. Pharmacol., 84, 204, 10.1111/bcp.13406 · DOI
  48. Li, 2018, Suspected drug-induced liver injury associated with iguratimod: a case report and review of the literature, BMC Gastroenterol., 18, 130, 10.1186/s12876-018-0858-z · DOI
  49. Liao, 2019, A rare case of cefepime-induced cholestatic liver injury, Tzu Chi. Med. J., 31, 124, 10.4103/tcmj.tcmj_151_18 · DOI
  50. Licata, 2017, A focus on epidemiology of drug-induced liver injury: analysis of a prospective study, Eur. Rev. Med. Pharmacol. Sci., 21, 112
  51. Lim, 2014, A challenge for diagnosing acute liver injury with concomitant/sequential exposure to multiple drugs: can causality assessment scales be utilized to identify the offending drug, 10.1155/2014/156389 · DOI
  52. Liu, 2018, The diagnostic role of miR-122 in drug-induced liver injury. A systematic review and meta-analysis, Medicine, 97, 49, 10.1097/MD.0000000000013478 · DOI
  53. Lu, 2016, Clinical characteristics of drug-induced liver injury and related risk factors, Exp. Ther. Med., 12, 2606, 10.3892/etm.2016.3627 · DOI
  54. Marrone, 2017, Drug-induced liver injury 2017: the diagnosis is not easy but always to keep in mind, Eur. Rev. Med. Pharmacol. Sci., 21, 122
  55. Matanovic, 2016, Changes to protocol in the regulation of adverse drug reactions –historical and current European view, Clin Res. Reg. Affairs, 33, 49, 10.3109/10601333.2016.1151610 · DOI
  56. McEuen, 2017, Associations of drug lipophilicity and extent of metabolism with drug-induced liver injury, Int. J. Mol. Sci., 18, 1335, 10.3390/ijms18071335 · DOI
  57. Medina-Caliz, 2016, Definition and risk factors for chronicity following acute idiosyncratic drug-induced liver injury, J. Hepatol., 65, 532, 10.1016/j.jhep.2016.05.003 · DOI · Paper page
  58. Meunier, 2018, Viewpoint: recent advances in hepatotoxicity on non steroidal anti-inflammatory drugs, Ann. Hepatol., 17, 187, 10.5604/01.3001.0010.8633 · DOI
  59. Morales, 2016, Hepatoxicity: a drug-induced cholestatic pattern, Rev. Col. Gastroenterol., 31, 34
  60. Moreno, 2015, Recurrent drug-induced liver injury (DILI) with ciprofloxacin and amoxillin/clavunate, Rev. Esp. Enferm. Dig., 107, 767, 10.17235/reed.2015.3810/2015 · DOI
  61. Naiqiong, 2017, A multicenter and randomized controlled trial of Bicyclol in the treatment of statin-induced liver injury, Med. Sci. Monit., 23, 5760, 10.12659/MSM.904090 · DOI
  62. Nicoletti, 2017, International Drug-Induced Liver Injury Consortium (iDILIC). Association of liver injury from specific drugs or group of drugs with polymorphisms in HLA and other genes in a Genome-wide Association Study, Gastroenterology, 152, 1078, 10.1053/j.gastro.2016.12.016 · DOI · Paper page
  63. Nicoletti, 2019, International Drug-Induced Liver Injury Consortium (iDILIC). Drug-induced liver injury due to Flucloxacillin: Relevance of multiple human leukocyte antigen alleles
  64. Niijima, 2017, Drug-induced liver injury caused by Ipragliflozin administration with causality established by a positive lymphocyte transformation test (LTT) and the Roussel Uclaf Causality Assessment Method (RUCAM): a case report, Ann. Hepatol., 16, 308, 10.5604/16652681.1231594 · DOI
  65. Ou, 2015, Causes, clinical features and outcomes of drug-induced liver injury in hospitalized patients in a Chinese tertiary care hospital, SpringerPlus, 4, 802, 10.1186/s40064-015-1600-8 · DOI
  66. Ortega-Alonso, 2016, Case characterization, clinical features and risk factors in drug-induced liver injury, Int. J. Mol. Sci., 17, 714, 10.3390/ijms17050714 · DOI
  67. Patel, 2018, Drug-induced liver injury associated with the use of Everolimus in a liver transplantant patient
  68. Raschi, 2017, Drug-induced liver injury: towards early prediction and risk stratification, World J. Hepatol., 9, 30, 10.4254/wjh.v9.i1.30 · DOI
  69. Rathi, 2017, Drug induced liver injury at a tertiary hospital in India: etiology, clinical features and predictors of mortality, Ann. Hepatol., 16, 442, 10.5604/01.3001.0009.8600 · DOI · Paper page
  70. Real, 2019, Drug-induced liver injury: highlights of the recent literature, Drug Saf., 42, 365, 10.1007/s40264-018-0743-2 · DOI
  71. Regev, 2014, Causality assessment for suspected DILI during clinical phases of drug development, Drug Saf., 37, S47, 10.1007/s40264-014-0185-4 · DOI
  72. Robles-Diaz, 2016, Biomarker in DILI: one step forward, Front. Pharmacol., 7, 267, 10.3389/fphar.2016.00267 · DOI
  73. Robles-Diaz, 2015, Distinct phenotype of hepatotoxicity associated with illicit use of anabolic androgenic steroids, Aliment Pharmacol. Ther., 41, 116, 10.1111/apt.13023 · DOI · Paper page
  74. Russmann, 2014, Rivaroxaban postmarketing risk of liver injury, J. Hepatol., 61, 293, 10.1016/j.jhep.2014.03.026 · DOI
  75. Russo, 2014, Spectrum of statin hepatotoxicity: experience of the drug-induced liver injury network, Hepatology, 60, 679, 10.1002/hep.27157 · DOI
  76. Sarges, 2016, Drug-induced liver injury: highlights from a review of the 2015 literature, Drug Saf., 39, 10.1007/s40264-016-0427-8 · DOI
  77. Schueller, 2018, The role of miRNAs in the pathophysiology of liver diseases and toxicity, Int. J. Mol. Sci., 19, 261, 10.3390/ijms19010261 · DOI
  78. Senior, 2014, Evolution of the Food and Drug Administration approach to liver safety assessment for new drugs: current status and challenges, Drug Saf., 37, 17, 10.1007/s40264-014-0182-7 · DOI
  79. Seyfarth, 2014, Genetic susceptibility to hepatoxicity due to bosentan treatment in pulmonary hypertension, Ann. Hepatol., 13, 803, 10.1016/S1665-2681(19)30983-4 · DOI
  80. Shahbaz, 2017, Highlights of drug- and herb-induced liver injury in the literature from 2016: how best to translate new information into clinical practice, Exp. Opin. Drug Metab. Toxicol., 13, 935, 10.1080/17425255.2017.1362391 · DOI · Paper page
  81. Sobhonslidsuk, 2016, The incidence, presentation, outcomes, risk of mortality and economic data of drug-induced liver injury from a national database in Thailand: a population-base study, BMC Gastroenterol., 16, 135, 10.1186/s12876-016-0550-0 · DOI
  82. Tan, 2018, Systematic review and meta-analysis of algorithms used to identify drug-induced liver injury (DILI) in health record databases, Liver Int., 38, 742, 10.1111/liv.13646 · DOI
  83. Taneja, 2017, Acute liver failure due to Etodolac, a selective cyclogenase-2 (COX-2) inhibitor Non-steroidal anti-inflammatory drug established by RUCAM-based causality assessment, Ann. Hepatol., 16, 818, 10.5604/01.3001.0010.2829 · DOI
  84. Tang, 2015, Acute hepatocellular drug-induced liver injury from Bupropion and Doxycycline, ACG Case Rep. J., 3, 66, 10.14309/crj.2015.103 · DOI
  85. Tao, 2018, Genetic polymorphisms of UGT 1A1 and susceptibility to anti-tuberculosis drug-induced liver: a RUCAM-based case-control study, Int. J. Immunopathol. Pharmacol., 32, 1, 10.1177/2058738418816288 · DOI
  86. Terziroli Beretta-Piccoli, 2017, Atovaquone/Proguanil-induced autoimmune-like hepatitis, Hepatol. Commun., 1, 293, 10.1002/hep4.1039 · DOI
  87. Teschke, 2015, Editorial. Drug-induced liver injury: expanding our knowledge by enlarging population analysis with prospective and scoring causality assessment, Gastroenterology, 148, 1271, 10.1053/j.gastro.2015.04.027 · DOI
  88. Teschke, 2016, Diagnosis and management of drug-induced liver injury (DILI) in patients with pre-existing liver disease, Drug Saf., 39, 729, 10.1007/s40264-016-0423-z · DOI
  89. Teschke, 2016, Traditional Chinese Medicine (TCM) and herbal hepatotoxicity: RUCAM and the role of novel diagnostic biomarkers such as microRNAs, Medicines, 3, 18, 10.3390/medicines3030018 · DOI · Paper page
  90. Teschke, 2017, Editorial. Prospective Indian study of DILI with confirmed causality using the Roussel Uclaf Causality Assessment Method (RUCAM): a report of excellence, Ann. Hepatol., 16, 324, 10.5604/16652681.1235471 · DOI
  91. Teschke, 2017, Drug induced liver injury: can biomarkers assist RUCAM in causality assessment? Special issue: molecular research on drug induced liver injury, Int. J. Mol. Sci., 18, 803, 10.3390/ijms18040803 · DOI
  92. Teschke, 2017, Exp. Opin. Drug Metab. Toxicol., 13, 425, 10.1080/17425255.2017.1252749 · DOI
  93. Teschke, 2018, Commentary. Drug- and herb-induced liver injury in 2016 with highly appreciated critical comments: related or not, that is the question, Clin. Diagn. Pathol., 2, 1, 10.15761/CDP.1000122 · DOI
  94. Teschke, 2018, Causality assessment methods in drug-induced liver injury. In: Drug-induced Liver Toxicity (Chapter 27), 555
  95. Teschke, 2018, Review: drug induced liver injury with analysis of alternative causes as confounding variables, Br. J. Clin. Pharmacol., 84, 1467, 10.1111/bcp.13593 · DOI
  96. Teschke, 2018, Review. Top-ranking drugs out of 3312 drug-induced liver injury cases evaluated by the Roussel Uclaf Causality Assessment Method, Exp. Opin. Drug Metab. Toxicol., 14, 1169, 10.1080/17425255.2018.1539077 · DOI · Paper page
  97. Teschke, 2018, Paracetamol (acetaminophen), alcohol, and liver injury: biomarkers, clinical issues, and experimental aspects, SL Pharmacol. Toxicol., 1, 113
  98. Teschke, 2019, Drug induced liver injury
  99. Tillmann, 2018, Novel approaches to causality adjudication in drug-induced liver disease, Curr. Hepatol. Rep, 17, 276, 10.1007/s11901-018-0416-8 · DOI
  100. Veluswamy, 2014, Adverse drug reaction: pomalidomide-induced liver injury, Lancet, 383, 2125, 10.1016/S0140-6736(14)61030-8 · DOI
  101. Visentin, 2018, Drug-induced bile duct injury, Biochim. Biophys. Acta., 1864, 1498, 10.1016/j.bbadis.2017.08.033 · DOI
  102. Wang, 2017, Drug induced autoimmune hepatitis (DIAIH): pathological and clinical study, Biomed Res., 28, 6028
  103. Wang, 2016, Chronic hepatitis B infection and risk of antituberculosis drug-induced liver injury: systematic review and meta-analysis, J. Chin. Med. Assoc., 79, 368, 10.1016/j.jcma.2015.12.006 · DOI
  104. Wang, 2018, Risk factors for acute liver failure among inpatients with anti-tuberculosis drug-induced liver injury, J. Int. Med. Res., 26, 300060518811512, 10.1177/0300060518811512 · DOI
  105. Watkins, 2015, How to diagnose and exclude drug-induced liver injury, Dig. Dis., 33, 472, 10.1159/000374091 · DOI
  106. Weiler, 2015, Drug-induced liver injury: the dawn of biomarkers, F1000Prime Rep., 7, 34, 10.12703/P7-34 · DOI
  107. Yamashita, 2017, Idiosyncratic drug-induced liver injury: a short review, Hepatol. Commun., 1, 494, 10.1002/hep4.1064 · DOI
  108. Yang, 2016, Clinical characteristics of drug-induced liver injury and primary biliary cirrhosis, World J. Gastroenterol., 22, 7579, 10.3748/wjg.v22.i33.7579 · DOI
  109. Yu, 2017, CSH guidelines for the diagnosis and treatment of drug-induced liver injury, Hepatol. Int., 11, 221, 10.1007/s12072-017-9793-2 · DOI
  110. Zhu, 2016, Comparison between Chinese herbal medicine and Western medicine-induced liver injury of 1985 patients, J. Gastroenterol. Hepatol., 31, 1476, 10.1111/jgh.13323 · DOI · Paper page
  111. Zhu, 2015, Causes, features, and outcomes of drug-induced liver injury in 69 children from China, Gut. Liver, 9, 525, 10.5009/gnl14184 · DOI

Cited by

Sorted by citations

Metadata

Authors
Teschke, R.
Venue
Frontiers in Pharmacology
Publisher
Frontiers Media SA
Published
2019-07-23
Volume
10
ISSN
1663-9812
DOI
10.3389/fphar.2019.00730
PMC
PMC6664244
Cited by
62
References
2
Licence
creativecommons.org/licenses/by/4.0/ (vor)

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review